At TrimRx, our personalized approach considers these medications as part of a comprehensive service that includes doctor consultations, lab work, ongoing support, and shipping, all designed to facilitate a safe and effective weight loss journey
Novo Nordisks branded semaglutide portfolio Ozempic, Wegovy and Rybelsus reported combined sales of Rs 45 crore in March, registering a marginal decline of Rs 2 crore month-on-month
Month 1: 4-7 pounds (2-3% loss), Month 2: 9-14 pounds cumulative (3.5-5.5% loss), Month 3: 14-21 pounds cumulative (5.5-8% loss), Month 6: 30-44 pounds cumulative (12-17% loss), Month 12: 43-66 pounds cumulative (17-23% loss), Months 16-20: 50-70+ pounds cumulative (20-25% loss maximum)
Whilst pharmaceutical GLP-1 receptor agonists such as semaglutide are licensed for type 2 diabetes and weight management, there is growing interest in natural approaches to support the body's own GLP-1 production